- Home
- WNEB vs IPHA Comparison
WNEB vs IPHA Comparison
Compare WNEB & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNEB
- IPHA
- Stock Information
- Founded
- WNEB 1853
- IPHA 1999
- Country
- WNEB United States
- IPHA France
- Employees
- WNEB N/A
- IPHA N/A
- Industry
- WNEB Savings Institutions
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- WNEB Finance
- IPHA Health Care
- Exchange
- WNEB Nasdaq
- IPHA Nasdaq
- Market Cap
- WNEB 195.7M
- IPHA 160.1M
- IPO Year
- WNEB N/A
- IPHA 2019
- Fundamental
- Price
- WNEB $9.96
- IPHA $1.83
- Analyst Decision
- WNEB Buy
- IPHA Strong Buy
- Analyst Count
- WNEB 3
- IPHA 1
- Target Price
- WNEB $9.75
- IPHA $11.00
- AVG Volume (30 Days)
- WNEB 206.4K
- IPHA 11.9K
- Earning Date
- WNEB 07-22-2025
- IPHA 03-27-2025
- Dividend Yield
- WNEB 3.03%
- IPHA N/A
- EPS Growth
- WNEB N/A
- IPHA N/A
- EPS
- WNEB 0.53
- IPHA N/A
- Revenue
- WNEB $72,966,000.00
- IPHA $20,831,349.00
- Revenue This Year
- WNEB N/A
- IPHA $209.83
- Revenue Next Year
- WNEB $7.94
- IPHA $83.15
- P/E Ratio
- WNEB $17.40
- IPHA N/A
- Revenue Growth
- WNEB N/A
- IPHA N/A
- 52 Week Low
- WNEB $6.64
- IPHA $1.29
- 52 Week High
- WNEB $10.08
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- WNEB 55.14
- IPHA 35.62
- Support Level
- WNEB $9.28
- IPHA $1.71
- Resistance Level
- WNEB $9.39
- IPHA $1.92
- Average True Range (ATR)
- WNEB 0.22
- IPHA 0.09
- MACD
- WNEB 0.03
- IPHA -0.01
- Stochastic Oscillator
- WNEB 69.81
- IPHA 20.97
About WNEB Western New England Bancorp Inc.
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.